摘要
Abstract
Objective:To explore clinical efficacy and serum inflammatory factor use of alprostadil combined with telbivudine in treatment of hepatitis B virus-related cirrhosis,providing a theoretical basis for clinical treatment.Methods:98 patients with hepatitis B cirrhosis admitted in our hospital from June 2014 to June 2016,were selected.According to the random number table,patients were divided into telbivudine group (49 cases) and combined group (49 cases).On the basis of routine treatment,telbivudine group was given telbivudine,combined group was given telbivudine and alprostadil for 12 weeks.To observe and analyze the changes of serum HBV DNA levels,liver function and serum inflammatory factor.Results:After treatment,overall efficacy of combined group was significantly higher than that of telbivudine group (89.30％ VS.63.89％,P＜ 0.05).After treatment,the serum HBV and DNA levels of the two groups were significant lower than those before treatment,but there was no significant difference (P＞0.05) between two groups.After treatment,serum AST,ALT,Tbil,IL-6,IL-22 and hs-CRP levels of combined group were significantly lower than those of telbivudine group (P＜0.05).Conclusion:Alprostadil combined with telbivudine could reduce serum HBV DNA levels,improve liver function,and alleviate the inflammatory condition of patients with ghepatitis B virus-related cirrhosis.关键词
前列地尔/替比夫定/乙型肝炎肝硬化/炎性因子Key words
Alprostadil/Telbivudine/Hepatitis B virus-related cirrhosis/Inflammatory factor
